文献速递儿童青少年精神

哌甲酯治疗ADHD两年后持续获益:随机安慰剂对照撤药研究

Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study.
PubMed 文献 · Am J Psychiatry · 2019-05-21

结果显示继续治疗组ADHD-RS评分变化优于撤药组,差异为-4.6(95%CI=-8.7,-0.56),撤药组CGI-I恶化比例更高(40.4% vs 15.9%)。结论支持长期使用哌甲酯仍有效,但部分患者撤药后未恶化,支持定期评估继续治疗的必要性。

要点

  • 长期哌甲酯治疗2年后继续使用仍可显著改善ADHD症状。
  • 撤药组注意力不集中和多动分项恶化更明显。
  • 部分患者撤药后未恶化,支持定期评估用药必要性。

核心结论

  • 长期使用哌甲酯后继续治疗仍有效,但部分患者撤药后未出现恶化。

主要发现

  • 继续治疗组与撤药组基线ADHD-RS均值分别为21.4(SD=9.7)和19.6(SD=8.9),7周后分别为21.9(SD=10.8)和24.7(SD=11.4)。
  • 两组ADHD-RS评分变化差异为-4.6(95%CI=-8.7,-0.56),有利于继续治疗组。
  • 撤药组ADHD-RS注意力不集中分项及CTRS-R:S多动分项和ADHD指数恶化显著更明显。
  • CGI-I显示撤药组恶化比例为40.4%,继续治疗组为15.9%。

临床怎么用

  • 支持指南建议对长期使用哌甲酯的患者定期评估是否仍有继续治疗的必要。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The benefits of long-term use of methylphenidate treatment in children and adolescents with attention deficit hyperactivity disorder (ADHD), as frequently prescribed in clinical practice, are unclear. The authors investigated whether methylphenidate remains beneficial after 2 years of use. METHODS: Ninety-four children and adolescents (ages 8-18 years) who had been treated in regular care with methylphenidate for more than 2 years were randomly assigned to double-blind continuation of treatment for 7 weeks (36 or 54 mg/day of extended-release methylphenidate) or gradual withdrawal over 3 weeks, to 4 weeks of placebo. The primary outcome measure was the investigator-rated ADHD Rating Scale (ADHD-RS); secondary outcome measures were the investigator-rated Clinical Global Impressions improvement scale (CGI-I) and the Conners' Teacher Rating Scale-Revised: Short Form (CTRS-R:S). Continuous ratings were analyzed with mixed model for repeated measures analyses, and the CGI-I with a chi-square test. RESULTS: The mean ADHD-RS scores at baseline for the continuation and discontinuation groups, respectively, were 21.4 (SD=9.7) and 19.6 (SD=8.9); after 7 weeks, the mean scores were 21.9 (SD=10.8) and 24.7 (SD=11.4), with a significant between-group difference in change over time of -4.6 (95% CI=-8.7, -0.56) in favor of the group that continued methylphenidate treatment. The ADHD-RS inattention subscale and the CTRS-R:S ADHD index and hyperactivity subscale also deteriorated significantly more in the discontinuation group. The CGI-I indicated worsening in 40.4% of the discontinuation group, compared with 15.9% of the continuation group. CONCLUSIONS: Continued treatment with methylphenidate remains effective after long-term use. Some individual patients may, however, be withdrawn from methylphenidate without deterioration. This finding supports guideline recommendations that patients be assessed periodically to determine whether there is a continued need for methylphenidate treatment.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Matthijssen AM, Dietrich A, Bierens M, et al. Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study. Am J Psychiatry. 2019. PMID: 31109200. doi:10.1176/appi.ajp.2019.18111296

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。